IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

TARELLA, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.290
AS - Asia 8.325
NA - Nord America 7.854
SA - Sud America 907
AF - Africa 199
OC - Oceania 89
Continente sconosciuto - Info sul continente non disponibili 15
Totale 28.679
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.509
GB - Regno Unito 3.740
CN - Cina 2.693
DE - Germania 2.173
SG - Singapore 2.169
IT - Italia 1.714
RU - Federazione Russa 814
HK - Hong Kong 801
BR - Brasile 654
SE - Svezia 594
VN - Vietnam 536
FR - Francia 489
IN - India 427
TR - Turchia 357
IE - Irlanda 351
BD - Bangladesh 331
KR - Corea 268
JP - Giappone 249
ES - Italia 234
NL - Olanda 229
CA - Canada 196
FI - Finlandia 194
UA - Ucraina 161
ID - Indonesia 154
CH - Svizzera 111
EU - Europa 103
PL - Polonia 100
MX - Messico 87
AU - Australia 82
AR - Argentina 66
CO - Colombia 61
GR - Grecia 54
BE - Belgio 49
DK - Danimarca 49
CI - Costa d'Avorio 48
AT - Austria 46
IQ - Iraq 42
TW - Taiwan 39
PH - Filippine 33
PK - Pakistan 33
EC - Ecuador 32
HR - Croazia 30
PT - Portogallo 30
SA - Arabia Saudita 27
ZA - Sudafrica 27
MA - Marocco 26
CZ - Repubblica Ceca 25
IL - Israele 25
CL - Cile 24
PE - Perù 24
VE - Venezuela 20
MY - Malesia 19
RO - Romania 19
TN - Tunisia 19
EG - Egitto 18
TH - Thailandia 18
IR - Iran 17
KE - Kenya 17
LT - Lituania 17
ET - Etiopia 16
JO - Giordania 15
UZ - Uzbekistan 15
PY - Paraguay 14
NP - Nepal 11
BA - Bosnia-Erzegovina 10
NO - Norvegia 10
HN - Honduras 9
JM - Giamaica 9
TT - Trinidad e Tobago 9
BY - Bielorussia 7
EE - Estonia 7
NZ - Nuova Zelanda 7
UY - Uruguay 7
CR - Costa Rica 6
SN - Senegal 6
AE - Emirati Arabi Uniti 5
BO - Bolivia 5
KZ - Kazakistan 5
OM - Oman 5
PA - Panama 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AZ - Azerbaigian 4
BG - Bulgaria 4
DZ - Algeria 4
GE - Georgia 4
HU - Ungheria 4
LB - Libano 4
NG - Nigeria 4
RS - Serbia 4
SI - Slovenia 4
DO - Repubblica Dominicana 3
GT - Guatemala 3
KG - Kirghizistan 3
LC - Santa Lucia 3
LU - Lussemburgo 3
MD - Moldavia 3
MK - Macedonia 3
NI - Nicaragua 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
Totale 28.727
Salva come PNG Salva come JPEG
Città #
Southend 3.358
Frankfurt am Main 1.474
Singapore 1.190
Hong Kong 704
Ashburn 593
Milan 489
Beijing 439
Seattle 434
San Jose 433
Chandler 414
Princeton 348
Dublin 347
Fairfield 337
Dallas 300
Wilmington 294
Council Bluffs 271
Los Angeles 213
Woodbridge 184
Lauterbourg 168
Houston 150
Guangzhou 147
Shanghai 147
Santa Clara 145
Bengaluru 141
Moscow 137
Redwood City 137
Ho Chi Minh City 135
Hanoi 133
New York 132
Redmond 125
Buffalo 124
Des Moines 118
Ann Arbor 117
Nanjing 116
Cambridge 111
Jacksonville 110
Hanover 105
Hefei 105
Tokyo 100
Mountain View 96
Dearborn 95
Jakarta 93
Hangzhou 89
Columbus 84
Rome 83
Sakarya 83
Tianjin 81
Berlin 79
Helsinki 78
Toronto 76
Boardman 70
The Dalles 66
Warsaw 64
Serra 63
São Paulo 62
Phoenix 60
Seoul 59
Barcelona 58
Shenyang 55
Chicago 54
Shenzhen 51
Nuremberg 49
London 47
Abidjan 46
Jinan 46
Cangzhou 45
Istanbul 45
Somerville 44
Turin 44
Bogotá 43
Andover 39
Ottawa 39
Nanchang 38
Central District 36
Paris 36
San Diego 34
Hebei 33
Madrid 33
Atlanta 31
Changsha 31
Wuhan 31
Bologna 28
Zhengzhou 28
Lugano 27
Mumbai 27
Trieste 27
Brussels 26
Athens 25
Naples 25
Boston 24
Fuzhou 24
Belo Horizonte 23
Munich 23
Vienna 23
Dong Ket 22
Falls Church 22
Haiphong 22
Chengdu 20
Jiaxing 20
Melbourne 20
Totale 17.370
Salva come PNG Salva come JPEG
Nome #
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 2.105
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas 885
Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art 671
The issue of refractory disease in follicular and other lymphoma subtypes 405
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 395
SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma 389
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 371
[¹⁸ F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma [$\less$sup$\greater$18$\less$/sup$\greater$F]-{FDG} {PET} radiomic model as prognostic biomarker in diffuse large B-cell lymphoma] 360
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 317
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 316
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 285
Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors : a single-center experience 278
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 262
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells 251
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 247
Thymoma and pure red cell aplasia with hypoplasia of megakaryocytopoiesis : A rare and life-treating condition 245
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation 239
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 232
Brief chemoimmunotherapy rituximab ®-FND +/- R maintenance is effective and safe newly diagnosed follicular lymphoma elderly patients : an intergruppo italiano linfomi (IIL) randomized trial 228
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade 227
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL 226
Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma 222
Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival 221
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas : pre-transplant disease status and histotype heavily influence outcome 217
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion : results from the National Registry of the Italian Drug Agency 217
Brief chemoimunotherapy with rituximab (R)- Find ± R maintenance as first treatment in adevanced follicular lymphoma (FL) in elderly : preliminary analysis of a prospective randomized trial 216
Brief chemoimmunoterapy rituximab (R)-FND ± R maintenance as first line treatment in elderly patients with advanced follicular lymphoma (FL) : preliminary analysis of a prospective randomized IIL trial 215
Haploidentical cellular therapy in elderly patients with acute myeloid leukemia : description of its use in high risk patients 215
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy 213
G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial) 209
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term 206
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 205
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 203
G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs 203
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo 203
Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation 201
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab : a 20-year retrospective follow-up study in patients with lymphoma 200
Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy 199
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study 192
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 190
High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma : a 10-year update of the R-HDS regimen 190
Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting : Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes 188
Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial 187
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma) 185
Erratum: Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 184
HHV8-negative effusion-based large B cell lymphoma arising in chronic myeloid leukemia patients under dasatinib treatment : A report of two cases 184
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation 183
Rituximab (R) maintenance versus observation after short term chemoimmunotherapy R-Find as first line treatment in elderly patients with advanced follicular lymphoma (FL) : updated results and safety of the maintenance of an Intergruppo Italiano Linfomi (ILL) randomized trial 182
Multipotent Mesenchymal Stromal Stem Cell Expansion by Plating Whole Bone Marrow at a Low Cellular Density : a More Advantageous Method for Clinical Use 182
Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial 181
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study 181
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study 179
Influence of Donor and Recipient Gender on Telomere Maintenanceafter Umbilical Cord Blood Cell Transplantation: A Study by the GruppoItaliano Trapianto Di Midollo Osseo 179
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis : the superior disease control of R-HDS does not translate into an overall survival advantage 178
Peripheral t‐cell lymphoma, not otherwise specified : Clinical manifestations, diagnosis, and future treatment 177
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 176
Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome 176
Reduced intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed non-Hodgkin’s and Hodgkin’s lymphomas 175
Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimula patients with Amyotrophic Lateral Sclerosis: results from a multicenter prospective trial 174
A phase I-II multicenter trial on G-CSF in ALS: final results and prospectives 173
Bone marrow transplantation for lymphoma CR1 172
A multicentre trial G-CSF in Amyotrophic Lateral Sclerosis 170
Early Serum TARC Reduction Predicts Prognosis in Advanced-Stage Hodgkin Lymphoma Patients Treated with a PET-Adapted Strategy 170
Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas 169
Primary mediastinal large B-cell lymphoma (PMLBCL) : long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B 168
The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial 167
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 166
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles : long-term results of the GITIL/FIL HD 0607 trial 165
The hidden genomic landscape of acute myeloid leukemia : Subclonal structure revealed by undetected mutations 164
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 164
Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases 163
A phase I-II multicentre study on G-CSF in Amyotrophic Lateral Sclerosis 163
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders 161
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial 160
A phase I-II Multicenter Study on G-CSF in ALS: Clinical and Hematological Results 159
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement : Final Results of a Multicenter Phase II Trial 158
Minced umbilical cord fragments as a source of cells for orthopaedic tissue engineering: an in vitro study 156
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma 154
Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients 148
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 146
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 145
Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting 145
Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma 144
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma : a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence 144
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies 141
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting : evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3 140
Successful second autologous engraftment after long duration storage of hematopoietic stem cells 140
Risk-assessment in diffuse large cell lymphoma at first relapse : a study by the Italian Intergroup for Lymphomas 140
High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) 139
Efficacy of venetoclax based salvage chemotherapy followed by “Minimal Residual Disease driven”-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia 136
Long-term lymphoma survivors following high-dose chemotherapy and autograft : evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir 135
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment 135
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting 135
Long-term molecular remission after conventional chemotherapy in a patient with Philadelphia-negative acute lymphoblastic leukemia 134
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms : a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy 134
CD34-positive cells: biology and clinical relevance 133
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 131
Prognostic impact of baseline immunologic profile in aggressive b-cell non-hodgkin's lymphomas 131
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies 130
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity 130
Totale 22.480
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.989
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.989
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021179 0 0 0 0 0 0 0 0 0 0 0 179
2021/20222.450 194 147 258 150 228 110 136 215 269 210 130 403
2022/20232.439 343 161 166 207 229 472 95 157 268 81 140 120
2023/20242.751 146 178 161 111 330 145 282 272 133 255 368 370
2024/20254.314 322 440 235 361 302 209 170 409 235 360 361 910
2025/20268.061 656 465 884 738 732 570 952 532 1.123 491 723 195
Totale 29.957